RXRX vs UBER · rev $58.8M vs P/E 18, rev $52.02B
Recursion Pharmaceuticals Inc (RXRX) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
RXRX currently screens at market cap $1.75B. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the RXRX and UBER stock pages for the full models.
Not investment advice.